Harrow, Inc. Debt Instrument, Interest Rate, Effective Percentage
Harrow, Inc. (HROW) had Debt Instrument, Interest Rate, Effective Percentage of 9.20% as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentInterestRateEffectivePercentage · last filed 2026-03-02
- 2025-12-31: Debt Instrument, Interest Rate, Effective Percentage 9.20%.
- 2024-12-31: Debt Instrument, Interest Rate, Effective Percentage 10.74%.
- 2023-12-31: Debt Instrument, Interest Rate, Effective Percentage 10.58%.
| Period end | Debt Instrument, Interest Rate, Effective Percentage |
|---|---|
| 2025-12-31 | 9.20% 10-K · filed 2026-03-02 |
| 2024-12-31 | 10.74% 10-K · filed 2026-03-02 |
| 2023-12-31 | 10.58% 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |